Dr Megan Webster - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Dr Megan Webster

Senior Scientist

Originally from Leeds, Megan first moved to Newcastle to complete her Masters and PhD studies focusing on oral drug bioavailability and drug metabolism in the small intestine. After completing her PhD, Megan moved to the USA and completed her post-doc at the University of North Carolina, Chapel Hill where she worked on developing treatments for upper airway lung diseases, with a specific focus on cystic fibrosis. Having worked in collaboration with several pharmaceutical companies, Megan transitioned into industry, joining the Immunology and Respiratory Department at Boehringer-Ingelheim, Germany. Here Megan was responsible for leading lung fibrosis early stage drug discovery projects from initial conception through to lead optimisation. Megan also supervised Masters and PhD students to develop disease-relevant lung models applicable for drug discovery. Ready to move back to the UK, Megan joined Newcells Biotech in 2020 as is responsible for the development of both iPSC derived, and primary lung models and their applicability to drug discovery and lung disease. Outside of work Megan enjoys spending her time testing out new recipes and finally being able to spend regular time with her family!

Headshot of Dr Megan Webster